Session: SAT 554-583-Male Reproductive Endocrinology & Case Reports
Poster Board SAT-576
Methods: RHYME is a multi-center registry of 999 men with clinically-diagnosed HG (naïve to androgen treatment) from 25 sites in 6 European countries (DE/ES/IT/NL/SE/UK). ED, PDE5i use, and low sexual desire were assessed in all patients (n=999) by medical record review. In sexually active patients (N=752), ED and low sexual desire were also assessed by the IIEF sexual desire (SD) and erectile function (EF) domains. Serum T at baseline was assessed by mass spectrometry. Differences in geometric mean T in relation to sexual activity, ED, PDE5i use and low sexual desire were assessed via linear regression models.
Results: The mean age of the cohort was 59.1±10.5y and mean baseline T was 9.5±1.6nmol/L. More than three quarters (76.4%) of the sample were sexually active at the time of enrollment and sexually active hypogonadal men had higher baseline T relative to inactive men (9.9 vs 8.5nmol/L; p<.001). High overall rates of sexual dysfunction were observed in both sexually active and inactive participants. 64.7% of the total sample presented with decreased desire and 81.0% with loss of erection. Those with complaints of low desire had significantly lower mean T than those without (9.3 vs 10.0 nmol/L; p=0.03). Based on IIEF-EF scores in sexually active men, 34.8% had severe ED, 31.1% had moderate ED, and 34.1% had mild or no ED. While men with ED (presenting complaints or severe/moderate IIEF scores) did not have lower T overall, those being treated with PDE5i had significantly higher mean T than untreated men (11.0 vs 9.1nmol/L, p<0.0001). Rates of PDE5i use were highest in ES (44.2%) and lowest in Italy (9.4%), and were more than twice as high in urology (35.9%) compared to endocrinology or general medicine (16.1%) practices.
Conclusions: Prevalence of sexual dysfunction and rates of PDE5i use are high in our large cohort of European hypogonadal men before starting androgen treatment, although substantial variations were observed by practice specialty and country. PDE5i use was associated with higher endogenous T in men with ED whereas loss of sexual desire and sexual inactivity were associated with the lowest levels of T.
Disclosure: RCR: Consultant, Eli Lilly & Company, Consultant, Ferring Pharmaceuticals, Principal Investigator, Bayer Health Care. MM: Consultant, Eli Lilly & Company, Consultant, Bayer, Inc.. HMB: Speaker, Jenapharma, Consultant, Lilly USA, LLC. FCWW: Consultant, Eli Lilly & Company, Consultant, Galapagos ( Mechelen, Belgium), Consultant, Ligand Pharmaceuticals Inc (San Diego, CA), Consultant, Novartis Pharmaceuticals, Speaker, Bayer Schering Pharma, Speaker, Eli Lilly & Company. GRC: Consultant, Ligand Pharmaceuticals, Consultant, Clarus, Consultant, Repros Therapeutics, Member of advisory committees or review panels, Ferring Pharmaceuticals, Member of advisory committees or review panels, Abbott Laboratories, Clinical Researcher, Abbott Laboratories. ABA: Principal Investigator, Abbott Laboratories, Principal Investigator, GlaxoSmithKline, Consultant, Eli Lilly & Company. Nothing to Disclose: TMC, JFM
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters